explore -WSS

explore

author：Wikipedia 2025-08-26 23:47:19 - browse：367

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： How to save health care price transparency rules

WSS

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

WuXi out of biotech trade group, U.S. and China relations to blame

Male and female sex labels in research insufficient, scientists say

Pushing for an NIH office for post

Doctors on social media are being harassed and cyberbullied

Why scientists need input from humanists on sensitive research

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Medicare details structure of new drug price negotiation program

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

How to save health care price transparency rules

Medicare details structure of new drug price negotiation program

Here’s what’s in the FDA plan to include pregnant women in clinical trials

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

How one medical school became remarkably diverse

Artificial intelligence use in health care faces greater scrutiny in 2024

Wikipedia

John Green on his newest strategy for fighting tuberculosis

AMAs digital advisors table RPM coding reform proposal, again

Male and female sex labels in research insufficient, scientists say

Amid AI frenzy, a top HHS official's quest to create safeguards

President Biden's budget: Here's what you might have missed

Why depression after traumatic brain injury is distinct

focus

leisure time

hotspot

hotspot